A randomized phase II trial of efficacy and safety of the immunotherapy ALECSAT as an adjunct to radiotherapy and temozolomide for newly diagnosed glioblastoma.

Katja WerleniusGiuseppe StragliottoMichael StrandeusMalin BlomstrandHelena CarénAsgeir S JakolaBertil RydenhagDorte DyregaardKarine N DzhandzhugazyanAlexei F KirkinMartin K RaidaAnja SmitsSara Kinhult

Published in: Neuro-oncology advances (2021)

Addition of ALECSAT immunotherapy to standard treatment with radiochemotherapy was well tolerated but did not improve PFS or OS for patients with newly diagnosed GBM.

Keyphrases

newly diagnosed
locally advanced
early stage
radiation therapy
squamous cell carcinoma
open label
randomized controlled trial
clinical trial